NHG’s client – a private equity firm focused on investing in prominent technology companies – was planning to invest in a medication robotics company based in the Nordic region. The client needed commercial due diligence performed on the target company regarding risks and opportunities, and was seeking a CDD provider who possessed an in-depth understanding of the health and social care sector, including technology.
NHG supported its client by providing a buy-side commercial due diligence assessment on the target company. NHG’s work included an in-depth analysis of the underlying service industry fundamentals, target core market dynamics and outlook, competitive landscape, and potential competition impact on the target’s market position, and pricing and revenue outlook. In addition, the project included an initial assessment of global markets feasibility for the target company technology (Germany, France, UK, Italy, Spain, Canada, Japan, South Korea).
NHG’s client made a decision to acquire a majority share in the target company. After the investment was completed, NHG additionally supported the target company with an in-depth analysis and prioritization of adjacent growth opportunities in the Nordic social care markets. Two years after the investment, the company had been able to grow its revenue 2-3 fold in the Nordics and was selected for the Financial Times FT-1000 list of the fastest growing companies in Europe.